Catalent, Inc. is investing $200 million in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity.  The three-year program will expand the company’s biologics manufacturing sites in Madison, WI and Bloomington, IN.  This follows a recent announcement to invest $14 million in packaging capabilities at the Bloomington site.   Mammalian cell culture capacity will be increased at Madison with the build out of two new suites, each with a 2 x 2,...